Old Web
English
Sign In
Acemap
>
authorDetail
>
Shingo Tanaka
Shingo Tanaka
Takeda Pharmaceutical Company
Diabetes mellitus
Medicine
Pharmacokinetics
Pharmacodynamics
Placebo
6
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (6)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects
2018
Basic & Clinical Pharmacology & Toxicology
Kumi Matsuno
Shingo Kuroda
Shingo Tanaka
Hiroyuki Nakamichi
Tomoya Kagawa
Emiko Koumura
Show All
Source
Cite
Save
Citations (3)
A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
2018
The Journal of Clinical Pharmacology
Kumi Matsuno
Shingo Tanaka
Takamasa Hashimoto
Hiroyuki Nakamichi
Tomoya Kagawa
Emiko Koumura
Show All
Source
Cite
Save
Citations (3)
Phase I Clinical Trial of NE-58095 DR, a Risedronate Delayed-Release Tablet: Dose Escalation and Food Effect
2018
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics
Hiroyuki Fukase
Shingo Tanaka
Hiroaki Ohishi
Ichiro Oikawa
Hidetoshi Furuie
Show All
Source
Cite
Save
Citations (1)
Characterization of APOE and TOMM40 allele frequencies in the Japanese population
2017
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Akira Nishimura
Hidenori Nonomura
Shingo Tanaka
Michihiro Yoshida
Yuka Maruyama
Yutaka Aritomi
Ann M. Saunders
Daniel K. Burns
Michael W. Lutz
Grant Runyan
Eric Lai
Kumar Budur
Allen D. Roses
Show All
Source
Cite
Save
Citations (11)
MO020SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF SINGLE DOSES OF TAK-272, A NOVEL RENIN INHIBITOR, IN HEALTHY MALE SUBJECTS
2017
Nephrology Dialysis Transplantation
K. Matsuno
Shingo Kuroda
Shingo Tanaka
H Nakamichi
E Komura
Show All
Source
Cite
Save
Citations (3)
SP428A RANDOMIZED, SINGLE-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF TAK-272 IN HEALTHY ADULT NON-ELDERLY AND ELDERLY MALE SUBJECTS
2017
Nephrology Dialysis Transplantation
K. Matsuno
Shingo Tanaka
T. Hashimoto
H Nakamichi
E Komura
Show All
Source
Cite
Save
Citations (4)
1